CALA — Calithera Biosciences Share Price
Last trade - 00:00- $0.02m
- -$25.43m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0 | ||
| Price to Tang. Book | 0 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -197.66% | ||
| Return on Equity | -61.29% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 22.25 | n/a | n/a | 9.75 | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Calithera Biosciences, Inc. is a shell company. The Company is winding up its operations. The Company is seeking to sell all of its clinical assets and programs. The Company has not generated any revenue.
Directors
- Susan Molineaux PRE (67)
- Stephanie Wong CFO (47)
- Sumita Ray SVP (47)
- Christopher Molineaux SVP (67)
- Francesco Parlati SVP (52)
- Eric Sjogren SVP (64)
- Emil Kuriakose OTH
- Deepa Pakianathan LED (56)
- Keith Orford DRC (49)
- Sunil Agarwal IND (51)
- Jonathan Drachman IND (59)
- Scott Garland IND (52)
- Suzy Jones IND (55)
- Blake Wise IND (50)
- H. Ward Wolff IND (72)
- Last Annual
- December 31st, 2022
- Last Interim
- December 31st, 2022
- Incorporated
- March 9th, 2010
- Public Since
- October 2nd, 2014
- No. of Shareholders
- 13
- No. of Employees
- 8
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 4,872,497
- Address
- 343 Oyster Point Blvd #200, SOUTH SAN FRANCISCO, 94080
- Web
- https://www.calithera.com/
- Phone
- +1 6508701000
- Auditors
- Ernst & Young LLP
Upcoming Events for CALA
Similar to CALA
Acusphere
Pink Sheets on Nasdaq
Adorbs
Pink Sheets on Nasdaq
Agentix
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
Aida Pharmaceuticals
Pink Sheets on Nasdaq
FAQ
As of Today at 19:44 UTC, shares in Calithera Biosciences are trading at $0.01. This share price information is delayed by 15 minutes.
Shares in Calithera Biosciences last closed at $0.01 and the price had moved by -90% over the past 365 days. In terms of relative price strength the Calithera Biosciences share price has underperformed the S&P500 Index by -90.66% over the past year.
The overall consensus recommendation for Calithera Biosciences is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreCalithera Biosciences does not currently pay a dividend.
Calithera Biosciences does not currently pay a dividend.
Calithera Biosciences does not currently pay a dividend.
To buy shares in Calithera Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.01, shares in Calithera Biosciences had a market capitalisation of $0.02m.
Here are the trading details for Calithera Biosciences:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: CALA
Based on an overall assessment of its quality, value and momentum Calithera Biosciences is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Calithera Biosciences is $8.00. That is 159900% above the last closing price of $0.01.
Analysts covering Calithera Biosciences currently have a consensus Earnings Per Share (EPS) forecast of -$1.35 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Calithera Biosciences. Over the past six months, its share price has outperformed the S&P500 Index by +158.79%.
As of the last closing price of $0.01, shares in Calithera Biosciences were trading -69.47% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Calithera Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Calithera Biosciences' management team is headed by:
- Susan Molineaux - PRE
- Stephanie Wong - CFO
- Sumita Ray - SVP
- Christopher Molineaux - SVP
- Francesco Parlati - SVP
- Eric Sjogren - SVP
- Emil Kuriakose - OTH
- Deepa Pakianathan - LED
- Keith Orford - DRC
- Sunil Agarwal - IND
- Jonathan Drachman - IND
- Scott Garland - IND
- Suzy Jones - IND
- Blake Wise - IND
- H. Ward Wolff - IND